Category: Psychedelic Bulletin - Page 13 - Psychedelic Alpha

Read more about the article Psychedelic Bulletin: MindMed Co-Founder Resigns from Board; Global Coalition to Reschedule Psilocybin Emerges; We Review Psychedelic Research and Trials from 2021

Psychedelic Bulletin: MindMed Co-Founder Resigns from Board; Global Coalition to Reschedule Psilocybin Emerges; We Review Psychedelic Research and Trials from 2021

Post published:January 14, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: Big Pharma’s Foray Into Psychedelics; Psilocybin Trial Makes Headlines; Bill to Legalize Psilocybin in Washington State Filed

Psychedelic Bulletin: Big Pharma’s Foray Into Psychedelics; Psilocybin Trial Makes Headlines; Bill to Legalize Psilocybin in Washington State Filed

Post published:January 7, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: First Look at Field Trip’s FT-104 Molecule; MindMed Trial Halted by FDA, Changes at the Top

Psychedelic Bulletin: First Look at Field Trip’s FT-104 Molecule; MindMed Trial Halted by FDA, Changes at the Top

Post published:December 31, 2021
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: COMPASS’ “Infamous” Psilocybin Patent Challenged; atai Stock Price Tumbles As Lock-Up Expiry Date Arrives; UT Austin Launches Psychedelics Centre

Psychedelic Bulletin: COMPASS’ “Infamous” Psilocybin Patent Challenged; atai Stock Price Tumbles As Lock-Up Expiry Date Arrives; UT Austin Launches Psychedelics Centre

Post published:December 17, 2021
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: Our Dispatch from Horizons NYC; NIDA to Study Delix Compounds

Psychedelic Bulletin: Our Dispatch from Horizons NYC; NIDA to Study Delix Compounds

Post published:December 10, 2021
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: MAPS’ $70m Investment Vehicle; atai’s Increased Stake in COMPASS; SSRI Psilocybin Interaction Study

Psychedelic Bulletin: MAPS’ $70m Investment Vehicle; atai’s Increased Stake in COMPASS; SSRI Psilocybin Interaction Study

Post published:December 5, 2021
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: Microdosing Study Causes a Stir; COMPASS Secures 5th US Patent; Leave Toads Alone?

Psychedelic Bulletin: Microdosing Study Causes a Stir; COMPASS Secures 5th US Patent; Leave Toads Alone?

Post published:November 26, 2021
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: DEA Again Increases Psychedelics Production Quotas; MindMed Announces Microdosing Study; Shorter Trips?

Psychedelic Bulletin: DEA Again Increases Psychedelics Production Quotas; MindMed Announces Microdosing Study; Shorter Trips?

Post published:November 19, 2021
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: Deconstructing COMPASS Pathways’ Phase 2b Results

Psychedelic Bulletin: Deconstructing COMPASS Pathways’ Phase 2b Results

Post published:November 15, 2021
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: COMPASS Targets PTSD; Detroit Decriminalizes Psychedelics; We Speak to Rick Doblin

Psychedelic Bulletin: COMPASS Targets PTSD; Detroit Decriminalizes Psychedelics; We Speak to Rick Doblin

Post published:November 5, 2021
Post category:Psychedelic Bulletin

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.